Phase 3
Completed N=2,103
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
Source: ClinicalTrials.gov NCT01854645 ↗Enrolled (actual)
2,103
Serious AEs
7.7%
Results posted
Mar 2017
Primary outcomePrimary: Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 — 0.126; 0.066; 0.062; 0.105 Liters
◆ Published Evidence
Established
57citations · ~6 / year
Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD.
Summary
The overall objective of this study is to assess the efficacy and safety of treatment with PT003 (GFF MDI), PT005 (FF MDI), PT001 (GP MDI), and open-label tiotropium bromide inhalation powder compared with each other and Placebo MDI over 24 weeks in subjects with moderate to very severe COPD.
Linked Publications (4)
-
Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD.
-
Predictive modeling of COPD exacerbation rates using baseline risk factors.
-
Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
-
Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 |
0.126; 0.066; 0.062; 0.105; -0.024 | — |
| SECONDARY Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks |
0.150; 0.091; 0.086; 0.122; -0.007 | — |
| SECONDARY St. George's Respiratory Questionnaire (SGRQ) Score |
-3.1; -1.2; -2.4; -2.7; -0.8 | — |
| SECONDARY Rescue Ventolin Hydrofluoroalkane (HFA) Use |
-0.8; -0.5; -0.8; -0.4; 0.3 | — |
| SECONDARY Onset of Action as Assessed by FEV1 |
0.185; 0.042; 0.182; 0.048; -0.002; 0.226 | <0.0001 sig |
| SECONDARY Peak Change From Baseline in FEV1 Within 2 Hours Post-dose |
0.356; 0.223; 0.263; 0.259; 0.065 | — |
Eligibility Criteria
Key Inclusion Criteria
- Male or female subjects at least 40 years of age and no older than 80 at Visit 1.
- Subjects with an established clinical history of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS)
- Current or former smokers with a history of at least 10 pack-years of cigarette smoking.
- Average f the -60 and the -30 min pre-dose FEV1 assessments must be < 80% predicted normal value calculated using National Health and Nutrition Examination Survey (NHANES) III reference equations.
- Subjects willing and, in the opinion of the investigator, able to adjust current COPD therapy as required by the protocol
Key Exclusion Criteria
- Significant diseases other than COPD, i.e. disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study
- Current diagnosis of asthma or alpha-1 antitrypsin deficiency
- Other active pulmonary disease such as active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, idiopathic interstitial pulmonary fibrosis, primary pulmonary hypertension, or uncontrolled sleep apnea
- Hospitalized due to poorly controlled COPD within 3 months prior to screening or during the Screening Period
- Poorly controlled COPD, defined as acute worsening of COPD that requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to screening or during the Screening Period
- Lower respiratory tract infections that required antibiotics within 6 weeks prior to screening or during the Screening Period
- Unstable ischemic heart disease, left ventricular failure, or documented myocardial infarction within 12 months of enrollment.
- Recent history of acute coronary syndrome, percutaneous coronary intervention, coronary artery bypass graft within the past three months
- Congestive heart failure (CHF) New York Heart Association (NYHA) Class III/IV)
- Clinically significant abnormal 12-lead ECG
- Abnormal liver function tests defined as aspartate transaminase (AST), alanine transaminase (ALT), or total bilirubin ≥ 1.5 times upper limit of normal at Visit 1 and on repeat testing
- Cancer not in complete remission for at least five years
- History of hypersensitivity to β2-agonists, glycopyrronium or other muscarinic anticholinergics, lactose/milk protein or any component of the MDI
Other protocol-defined inclusion/exclusion criteria may apply
Data sourced from ClinicalTrials.gov (NCT01854645) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.